Xiamen LP Pharm’s Generic Memantine:Donepezil HCl Receives Tentative Approval In U.S
Health Canada Issues Recall of Donepezil 10 mg Tablet
BOSTON, Sept. 12, 2023 /PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, announced today the publication of data reinforcing that ADLARITY (donepezil transdermal system) demonstrated favorable skin tolerability and adhesion in a placebo-controlled trial with healthy volunteers. ADLARITY, developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type. The data appear in the October-December 2023 issue of the peer-reviewed Alzheimer's Disease and Associated Disorders journal.
Corium, LLC, a commercial-stage biopharmaceutical company developing novel neuroscience therapies, and Lotus Pharmaceutical, a multinational pharmaceutical company, entered into an exclusive collaboration and license agreement for Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
Xiamen's Generic Memantine, Donepezil Receives Approval in the U.S.
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
BOSTON, March 14, 2022 /PRNewswire/ -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today the U.S. Food and Drug Administration (FDA) has approved Corium's ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type. ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal (GI) side effects associated with oral donepezil. ADLARITY is the first approved prescription drug product using Corium's proprietary CORPLEX transdermal technology, which has been used for years in consumer products.
SEOUL, South Korea--(BUSINESS WIRE)--Icure Pharmaceutical Inc. (KOSDAQ: 175250), a biopharmaceutical company in Korea, announced today that its donepezil patch, a treatment of Alzheimer’s-type dementia, received a drug product approval from the Ministry of Food and Drug Safety of Korea.
Enforcement Report - Week of September 8, 2021